REGENAPEP’s unique active ingredient, colostrum, is enriched with interleukin-1 receptor antagonist peptides (IL1RA) using a patent-pending production technology. IL1RA peptide, a natural amino acid complex, is a key blocker of the pro-inflammatory cytokine interleukin-1 (IL-1).
A significant body of research implicates IL-1 in the pathogenesis of arthritis. In both rheumatoid arthritis and osteoarthritis, IL-1 drives harmful musculoskeletal inflammation, leading to tissue destruction by inhibiting cell material synthesis and increasing the production of proteinase that are damaging to the overall joint structure. The effective inhibition of IL-1 using colostrum enriched with IL1RA peptides may significantly suppress inflammation and effectuate a cascade of ensuing benefits: pain reduction, prevention of disease deterioration and creation of better regenerative conditions for self-repair.
The botanical ingredients in REGENAPEP are demonstrated through clinical studies to cause anti-rheumatic and anti-inflammatory effects. They collectively block several inflammatory pathways by influencing cytokines that are key to causing inflammation.
Curcuma Longa reduces NF-κB, matrix metalloproteinases (MMPs) and prostaglandin E2; Salix Alba reduces IL-6 and TNF–α production; Harpagophytum Procumbens suppresses NF-κB and matrix metalloproteinases (MMPs); Boswellia Serrata decreases polymorphonuclear leukocyte infiltration and migration, and inhibits 5-lipoxygenase; Zingiber Officinale suppresses production of prostaglandin E2 and nitric oxide.